Loomis Sayles & CO L P Argenx Se Transaction History

Loomis Sayles & CO L P

$76.2 Billion
Q3 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$369.35 - $548.43 $5,909 - $8,774	-16 Reduced 15.69%	86 $42,000
Q1 2023 May 11, 2023	BUY	$334.23 - $403.65 $10,026 - $12,109	30 Added 41.67%	102 $38,000
Q4 2022 Feb 10, 2023	SELL	$342.17 - $402.31 $15.7 Million - $18.5 Million	-45,861 Reduced 99.84%	72 $27,000
Q3 2022 Nov 14, 2022	SELL	$343.2 - $395.75 $9.63 Million - $11.1 Million	-28,060 Reduced 37.92%	45,933 $16.2 Million
Q2 2022 Aug 05, 2022	SELL	$269.58 - $378.88 $4.01 Million - $5.64 Million	-14,877 Reduced 16.74%	73,993 $28 Million
Q1 2022 May 13, 2022	BUY	$254.45 - $351.06 $2.78 Million - $3.84 Million	10,933 Added 14.03%	88,870 $28 Million
Q4 2021 Feb 14, 2022	BUY	$272.01 - $353.03 $1.94 Million - $2.52 Million	7,142 Added 10.09%	77,937 $27.3 Million
Q3 2021 Nov 12, 2021	BUY	$295.0 - $350.58 $581,740 - $691,343	1,972 Added 2.87%	70,795 $21.4 Million
Q2 2021 Aug 13, 2021	BUY	$257.11 - $319.92 $692,654 - $861,864	2,694 Added 4.07%	68,823 $20.7 Million
Q1 2021 May 17, 2021	BUY	$268.3 - $380.31 $37,293 - $52,863	139 Added 0.21%	66,129 $18.2 Million
Q4 2020 Feb 12, 2021	SELL	$248.13 - $308.36 $2.18 Million - $2.71 Million	-8,799 Reduced 11.77%	65,990 $19.4 Million
Q3 2020 Nov 12, 2020	SELL	$215.51 - $272.51 $2.54 Million - $3.21 Million	-11,790 Reduced 13.62%	74,789 $19.6 Million
Q2 2020 Aug 14, 2020	SELL	$127.44 - $232.72 $23.5 Million - $43 Million	-184,579 Reduced 68.07%	86,579 $19.5 Million
Q1 2020 May 15, 2020	SELL	$108.83 - $165.23 $4.75 Million - $7.21 Million	-43,637 Reduced 13.86%	271,158 $35.7 Million
Q4 2019 Feb 14, 2020	SELL	$106.59 - $164.21 $743,465 - $1.15 Million	-6,975 Reduced 2.17%	314,795 $50.5 Million
Q3 2019 Nov 13, 2019	BUY	$113.31 - $150.51 $5.01 Million - $6.66 Million	44,226 Added 15.93%	321,770 $36.7 Million
Q2 2019 Aug 14, 2019	BUY	$115.0 - $141.58 $691,840 - $851,745	6,016 Added 2.22%	277,544 $39.3 Million
Q1 2019 May 15, 2019	BUY	$98.85 - $134.59 $242,775 - $330,553	2,456 Added 0.91%	271,528 $33.9 Million
Q4 2018 Feb 14, 2019	BUY	$63.81 - $109.82 $1.31 Million - $2.25 Million	20,509 Added 8.25%	269,072 $25.9 Million
Q3 2018 Nov 13, 2018	BUY	$75.5 - $96.63 $5.04 Million - $6.46 Million	66,811 Added 36.76%	248,563 $18.9 Million
Q2 2018 Aug 14, 2018	BUY	$74.84 - $100.16 $1.16 Million - $1.55 Million	15,507 Added 9.33%	181,752 $15.1 Million
Q1 2018 May 11, 2018	BUY	$56.95 - $85.19 $9.47 Million - $14.2 Million	166,245 New	166,245 $13.4 Million

Others Institutions Holding ARGX

# of Institutions

400

Shares Held

30.9M

Call Options Held

376K

Put Options Held

489K

Price T Rowe Associates Inc Baltimore, MD

5.82M
Shares

$3.28 Billion
0.36% of portfolio
Artisan Partners Limited Partnership Milwaukee, WI

3.51M
Shares

$1.98 Billion
2.99% of portfolio
Janus Henderson Group PLC London, X0

2.48M
Shares

$1.4 Billion
0.72% of portfolio
Capital World Investors Los Angeles, CA

1.7M
Shares

$959 Million
0.15% of portfolio
Avoro Capital Advisors LLC New York, NY

1.24M
Shares

$699 Million
10.11% of portfolio

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Loomis Sayles & CO L P, based on Form 13F filings with the SEC.

News

Stay updated on Loomis Sayles & CO L P with notifications on news.

Account